参考文献/References:
[1]Chen Y, Song Y, Du W, et al. Tumorassociated macrophages: an accomplice in solid tumor progression[J]. J Biomed Sci, 2019, 26(1):78.[2]林佳雯, 卫姣飞, 李淑琴. 肿瘤浸润免疫细胞与乳腺癌新辅助化疗敏感性及预后关系的研究进展[J]. 医学研究生学报, 2022, 35(4):437442.[3]王东轶, 沈俊逸, 陆乐, 等. 巨噬细胞极化失衡与类风湿关节炎疾病活动及骨侵蚀的相关性[J]. 医学研究生学报, 2021, 34(8):823828.[4]Yang H, Kim C, Zou W. Metabolism and macrophages in the tumor microenvironment[J]. Curr Opin Immunol, 2024, 91:102491.[5]Waibl Polania J, HoytMiggelbrink A, Tomaszewski WH, et al. Antigen presentation by tumorassociated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion[J]. Immunity, 2025, 58(1):232246.[6]Li M, Yang Y, Xiong L, et al. Metabolism, metabolites, and macrophages in cancer[J]. J Hematol Oncol, 2023, 16(1):80.[7]岳泽林, 王天华, 曲新田, 等. 肿瘤相关巨噬细胞在骨肉瘤中的作用及其靶向治疗的意义[J]. 中国肿瘤临床, 2024, 51(24):12851290.[8]Xiao M, Zhang J, Chen W, et al. M1like tumorassociated macrophages activated by exosometransferred THBS1 promote malignant migration in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1):143.[9]You Y, Tian Z, Du Z, et al. M1like tumorassociated macrophages cascade a mesenchymal/stemlike phenotype of oral squamous cell carcinoma via the IL6/Stat3/THBS1 feedback loop[J]. J Exp Clin Cancer Res, 2022, 41(1):10.[10]You G, Zheng Z, Huang Y, et al. scRNAseq and proteomics reveal the distinction of M2like macrophages between primary and recurrent malignant glioma and its critical role in the recurrence[J]. CNS Neurosci Ther, 2023, 29(11):33913405.[11]Liao Q, Deng H, Wang Z, et al. Deletion of prolyl hydroxylase domaincontaining enzyme 3 (phd3) in zebrafish facilitates hypoxia tolerance[J]. J Biol Chem, 2023, 299(12):105420.[12]Samanta D, Semenza GL. Metabolic adaptation of cancer and immune cells mediated by hypoxiainducible factors[J]. Biochim Biophys Acta Rev Cancer, 2018, 1870(1):1522.[13]林玲玲, 闫广智. 基于自噬途径的脐带间充质干细胞促进糖尿病模型创面愈合的作用机制[J]. 医学研究与战创伤救治, 2024, 37(5):472481.[14]蒋斌, 谢兴旺. SIRT2在结肠癌微环境CD4+T细胞向Th17细胞分化中的作用及对HIF1α的影响[J]. 中国免疫学杂志, 2023, 39(10):21962206.[15]Yang YF, Chang YC, Tsai KW, et al. UBE2C triggers HIF1αglycolytic flux in head and neck squamous cell carcinoma[J]. J Cell Mol Med, 2022, 26(13):37163725.[16]Yan Q, Liu J, Liu Y, et al. Tumorassociated macrophagederived exosomal miR215p promotes tumor angiogenesis by regulating YAP1/HIF1α axis in head and neck squamous cell carcinoma[J]. Cell Mol Life Sci, 2024, 81(1):179.[17]余涛, 陈远香, 刘施妍, 等. BMP9下调HIF1α抑制乳腺癌MDAMB231细胞的有氧糖酵解和迁移侵袭[J]. 中国药理学通报, 2024, 40(5):840846.[18]Yang Z, Su W, Wei X, et al. HIF1α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1[J]. Cell Rep, 2023, 42(8):112945.[19]Ni J, Wang X, Stojanovic A, et al. SingleCell RNA Sequencing of TumorInfiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF1α Unleashes NK Cell Activity[J]. Immunity, 2020, 52(6):10751087.[20]Zhang Y, Bian Y, Wang Y, et al. HIF1α is necessary for activation and tumourpromotion effect of cancerassociated fibroblasts in lung cancer[J]. J Cell Mol Med, 2021, 25(12):54575469.[21]Ramalho R, Rao M, Zhang C, et al. Immunometabolism: new insights and lessons from antigendirected cellular immune responses[J]. Semin Immunopathol, 2020, 42(3):279313.[22]Fang X, Zhao P, Gao S, et al. Lactate induces tumorassociated macrophage polarization independent of mitochondrial pyruvate carriermediated metabolism[J]. Int J Biol Macromol, 2023, 237:123810.[23]Wu JY, Huang TW, Hsieh YT, et al. CancerDerived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor[J]. Mol Cell, 2020, 77(2):213227.[24]Noe JT, Rendon BE, Geller AE, et al. Lactate supports a metabolicepigenetic link in macrophage polarization[J]. Sci Adv, 2021, 7(46):eabi8602.[25]Alexander RK, Liou YH, Knudsen NH, et al. Bmal1 integrates mitochondrial metabolism and macrophage activation[J]. Elife, 2020, 9:e54090.[26]Hong SM, Lee AY, Kim BJ, et al. NAMPTDriven M2 Polarization of TumorAssociated Macrophages Leads to an Immunosuppressive Microenvironment in Colorectal Cancer[J]. Adv Sci, 2024, 11(14):e2303177.[27]Chen F, Chen J, Yang L, et al. Extracellular vesiclepackaged HIF1αstabilizing lncRNA from tumourassociated macrophages regulates aerobic glycolysis of breast cancer cells[J]. Nat Cell Biol, 2019, 21(4):498510.[28]Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL1β through HIF1α[J]. Nature, 2013, 496(7444):238242.[29]Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumourassociated macrophages by tumourderived lactic acid[J]. Nature, 2014, 513(7519):559563.[30]Lu LG, Zhou ZL, Wang XY, et al. PDL1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma[J]. Gut, 2022, 71(12):25512560.[31]Liu D, Chang C, Lu N, et al. Comprehensive Proteomics Analysis Reveals Metabolic Reprogramming of TumorAssociated Macrophages Stimulated by the Tumor Microenvironment[J]. J Proteome Res, 2017, 16(1):288297.[32]Freemerman AJ, Johnson AR, Sacks GN, et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)mediated glucose metabolism drives a proinflammatory phenotype[J]. J Biol Chem, 2014, 289(11):78847896.[33]Kim JW, Tchernyshyov I, Semenza GL, et al. HIF1mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia[J]. Cell Metab, 2006, 3(3):177185.[34]Lecoultre M, Dutoit V, Walker PR. Phagocytic function of tumorassociated macrophages as a key determinant of tumor progression control: a review[J]. J Immunother Cancer, 2020, 8(2):e001408.[35]Li B, Yang Q, Li Z, et al. Expression of Monocarboxylate Transporter 1 in Immunosuppressive Macrophages Is Associated With the Poor Prognosis in Breast Cancer[J]. Front Oncol, 2020, 10:574787.[36]Fuhrmann DC, Brüne B. A graphical journey through iron metabolism, microRNAs, and hypoxia in ferroptosis[J]. Redox Biol, 2022, 54:102365.[37]Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022, 185(14):24012421.[38]Martin F, Linden T, Katschinski DM, et al. Copperdependent activation of hypoxiainducible factor (HIF)1: implications for ceruloplasmin regulation[J]. Blood, 2005, 105(12):46134619.[39]陈辰, 蒋敬庭. 氨基酸代谢在肿瘤微环境及免疫治疗中作用的研究进展[J]. 中国肿瘤生物治疗杂志, 2022, 29(1):6369.[40]郭锐, 于洋, 关海霞. 谷氨酰胺代谢在肿瘤发生发展中作用及机制[J]. 临床军医杂志, 2016, 44(6):652655.[41]Liu X, Yan Z, Cai J, et al. Glucose and glutaminedependent bioenergetics sensitize bone mechanoresponse after unloading by modulating osteocyte calcium dynamics[J]. J Clin Invest, 2023, 133(3):e164508.[42]Zheng X, Fernando V, Sharma V, et al. Correction of arginine metabolism with sepiapterinthe precursor of nitric oxide synthase cofactor BH(4)induces immunostimulatoryshift of breast cancer[J]. Biochem Pharmacol, 2020, 176:113887.[43]Cao Y, Wo M, Xu C, et al. An AMPK agonist suppresses the progress of colorectal cancer by regulating the polarization of TAM to M1 through inhibition of HIF1α and mTOR signal pathway[J]. J Cancer Res Ther, 2023, 19(6):15601567.[44]Cai Z, Li W, Hager S, et al. Targeting PHGDH reverses the immunosuppressive phenotype of tumorassociated macrophages through αketoglutarate and mTORC1 signaling[J]. Cell Mol Immunol, 2024, 21(5):448465.[45]Poczobutt JM, De S, Yadav VK, et al. Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer[J]. J Immunol, 2016, 196(6):28472859.[46]Wang P, Du X, Han Z, et al. Nuclear PHGDH regulates macrophage polarization through transcriptional repression of GLUD1 and GLS2 in breast cancer[J]. Cancer Biol Med, 2025, 22(5):502524.[47]Mantovani A, Allavena P, Marchesi F, et al. Macrophages as tools and targets in cancer therapy[J]. Nat Rev Drug Discov, 2022, 21(11):799820.[48]Annamalai RT, Turner PA, Carson WF, et al. Harnessing macrophagemediated degradation of gelatin microspheres for spatiotemporal control of BMP2 release[J]. Biomaterials, 2018, 161:216227.[49]Jeong W, Park SR, Rapisarda A, et al. Weekly EZN2208 (PEGylated SN38) in combination with bevacizumab in patients with refractory solid tumors[J]. Invest New Drugs, 2014, 32(2):340346.[50]Weng Q, Wang D, Guo P, et al. Q39, a novel synthetic Quinoxaline 1, 4DiNoxide compound with anticancer activity in hypoxia[J]. Eur J Pharmacol, 2008, 581(3):262269.[51]Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN2968, an antisense oligonucleotide inhibitor of hypoxiainducible factor1 alpha (HIF1α), in patients with refractory solid tumors[J]. Cancer Chemother Pharmacol, 2014, 73(2):343348.[52]Mie Lee Y, Kim SH, Kim HS, et al. Inhibition of hypoxiainduced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF1alpha activity[J]. Biochem Biophys Res Commun, 2003, 300(1):241246.[53]Zhang Y, Chen H, Shen Y, et al. Combined Effects of 2Methoxyestradiol (HypoxiaInducible Factor 1α Inhibitor) and Dasatinib (A SecondGeneration Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells[J]. J Immunol Res, 2022, 2022:6324326.[54]Zhao T, Ren H, Jia L, et al. Correction: Inhibition of HIF1α by PX478 enhances the antitumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma[J]. Oncotarget, 2019, 10(53):55695570.[55]Wang J, Yang C, Xu H, et al. The Interplay Between HIF1α and EZH2 in Lung Cancer and DualTargeted Drug Therapy[J]. Adv Sci, 2024, 11(7):e2303904.[56]Han HJ, Sivaraman A, Kim M, et al. HIF1α inhibition by MO2097, a novel chiralfree benzofuran targeting hnRNPA2B1[J]. J Adv Res, 2024, 64:6781.[57]莫小飞, 徐晓莉, 王亚楼, 等. 靶向HIF1α/p300蛋白蛋白相互作用抑制剂的研究进展[J]. 中国药科大学学报, 2017, 48(5):515522.[58]Yu T, Tang B, Sun X. Development of Inhibitors Targeting HypoxiaInducible Factor 1 and 2 for Cancer Therapy[J]. Yonsei Med J, 2017, 58(3):489496.